Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (6321)	5/13/2002 5:22:59 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

tuck, Isn't ESPR's drug an injectable protein? If so, it's not really competition for Advicor. Presambly it would be used only in extreme cases. All the pharmas are chasing an oral drug to raise HDL. PFE's CP-529,414 seems to be in the lead - I think it has completed Phase II trials. They are testing it both on its own and in conjunction with Lipitor. It still must be 4-5 years away from the market, though. Niaspan/Advicor have "usability" issues (the flushing) rather than much in the way of safety issues that I'm aware of. Peter